

November 30, 2021

Notice Regarding Reorganization of Subsidiary through Company Merger

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter, “Shionogi”), parent company of Shionogi Pharma Co., Ltd. (Head Office: Settsu, Osaka, Japan; President & CEO: Ryuichi Kume, Ph.D.; hereafter “Shionogi Pharma”), today announces Shionogi has resolved at a meeting of the Board of Directors on November 29, 2021 to have Shionogi Pharma implement an absorption-type merger (hereafter “Merger”) of its wholly owned subsidiary Nagase Medicals Co., Ltd. (Head Office: Itami, Hyogo, Japan; Representative Director and President: Mitsuru Akasaka; hereafter “Nagase Medicals”), aiming for completion of the Merger by April 1, 2022.

1. Purpose of Merger

Shionogi Pharma aims to become the “most trusted one-stop CDMO*”, and is expanding its business of manufacturing, sale, analytical testing and pharmaceutical engineering of medicinal drugs and investigational drugs. Nagase Medicals, a wholly owned subsidiary of Shionogi Pharma from October 1, 2020, is involved in the contract manufacture of high value-added healthcare products, focusing on highly potent injectable pharmaceuticals.

The Merger of the two businesses aims to create a faster and higher quality full-range CDMO and solutions business to increase customer value and drive growth as a technological innovation-focused manufacturing company. Through establishing a new business foundation, Shionogi Pharma will seek to create a diverse modality CDMO based on the group’s unique knowledge, technology, and experience, including in the manufacturing of high pharmacological activity APIs and drug products, solid and injectable, while also aiming to establish a new continuous manufacturing platform for API.

* Contract Development and Manufacturing Organization

2. Absorption-type merger

(1) Summary of the Merger

A) Schedule of the Merger

Approval of Merger by Shionogi’s Board of Directors	November 29, 2021
Approval of Merger agreement by Shionogi Pharma’s Board of Directors	December 17, 2021 (planned)
Conclusion date of Merger agreement	December 22, 2021 (planned)
Approval of Merger agreement by Shionogi Pharma Extraordinary General Meeting of Shareholders	February 2022 (planned)
Effective date of Merger	April 1, 2022 (planned)
Registration date of Merger	April 1, 2022 (planned)

B) Method of the Merger

The Merger is an absorption-type merger under which Shionogi Pharma shall be the company surviving the Merger, and Nagase Medicals shall be absorbed in the Merger.

(2) Outline of merging companies

	Company surviving the Merger (as of November 30, 2021)	Company absorbed in the Merger (as of November 30, 2021)
Company Name	Shionogi Pharma Co., Ltd.	Nagase Medicals Co., Ltd.
Major Business Areas	Manufacturing, sale, analytical testing and pharmaceutical engineering of medicinal drugs and investigational drugs	Development, manufacture and import/export of ethical drugs, medical equipment, medical materials and veterinary drugs
Date Established	October 1, 2018	July 1, 1972
Address	5-1, Mishima 2-chome, Settsu, Osaka	323, Senzo 4-chome, Itami, Hyogo
Representative	President and CEO Ryuichi Kume, Ph.D.	Representative Director and President Mitsuru Akasaka
Capital	90 million yen	498 million yen
End of Fiscal Year	March 31	March 31
Principal shareholders and investment ratio	Shionogi & Co., Ltd. 100.0%	Shionogi Pharma Co., Ltd. 100.0%

3. Prospects

We expect the impact of the Merger on Shionogi's consolidated business performance for the period ending March 31, 2022 to be minimal.

For further information, contact:

Shionogi Pharma Co., Ltd., Corporate Planning Department

TEL : +81-6-6381-7402

End of Document